A Phase 2a, Randomised, Double-blind, Parallel Study to Assess the Efficacy, Safety and Tolerability of AZD9567 compared to Prednisolone 20 mg in patients with active Rheumatoid Arthritis (RA)

Trial Profile

A Phase 2a, Randomised, Double-blind, Parallel Study to Assess the Efficacy, Safety and Tolerability of AZD9567 compared to Prednisolone 20 mg in patients with active Rheumatoid Arthritis (RA)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 14 May 2018

At a glance

  • Drugs AZD 9567 (Primary) ; Prednisolone
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Sponsors AstraZeneca; AstraZeneca AB
  • Most Recent Events

    • 26 Jan 2018 Planned End Date changed from 2 Jan 2019 to 15 Feb 2019.
    • 26 Jan 2018 Planned primary completion date changed from 2 Jan 2019 to 15 Feb 2019.
    • 26 Jan 2018 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top